GLP-1 and Medication

June 8, 2026 A perspective piece just published in the New England Journal of Medicine is sounding a clear warning: GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound) may pose serious risks for people with restrictive eating histories, including those who had an eating disorder years ago and consider themselves recovered. The NEJM authors describe case reports of dangerous appetite suppression, a return to restrictive patterns, and psychiatric com

June 3, 2026 A large new study of more than 600,000 veterans found that GLP-1 medications like Ozempic and Wegovy significantly reduced the development of substance use disorders, including alcohol, opioids, nicotine, and cocaine, and cut overdose rates by 40% in people already struggling with addiction. The researchers think these drugs may be doing something broader than managing weight or blood sugar: they may be acting on craving itself, quieting a shared biological signa